HRP20050556B1 - Supstituirani derivati 1-piperidin-4-il-4-pirolidin-3-il-piperazina i njihova upotreba kao antagonista receptora za neurokinin - Google Patents

Supstituirani derivati 1-piperidin-4-il-4-pirolidin-3-il-piperazina i njihova upotreba kao antagonista receptora za neurokinin

Info

Publication number
HRP20050556B1
HRP20050556B1 HRP20050556AA HRP20050556A HRP20050556B1 HR P20050556 B1 HRP20050556 B1 HR P20050556B1 HR P20050556A A HRP20050556A A HR P20050556AA HR P20050556 A HRP20050556 A HR P20050556A HR P20050556 B1 HRP20050556 B1 HR P20050556B1
Authority
HR
Croatia
Prior art keywords
disorders
antagonists
diseases
neurokinin
pyrrolidin
Prior art date
Application number
HRP20050556AA
Other languages
English (en)
Inventor
Frans Eduard Janssens
Francois Maria Sommen
Benoit Christian Albert Ghisla De Boeck
Joseph Elisabeth Leenaerts
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20050556A2 publication Critical patent/HRP20050556A2/xx
Publication of HRP20050556B1 publication Critical patent/HRP20050556B1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Ovaj izum odnosi se na supstituirane derivate 1-piperidin-4-il-4-pirolidin-3-il-piperazina koji djeluju antagonistički na receptor za neurokinin, posebno antagonistički na NK, antagonistički na NK/NKkombinirano i antagonistički na NK/NK/NKkombinirano, na njihovo pripravljanje, pripravke koji ih uključuju te njihovu uporabu kao lijeka, naročito za liječenje shizofrenije, anksioznosti, povraćanja i sindroma iritabilnog crijeva (IBS). Spojevi prema ovom izumu mogu se prikazati općom Formulom (I) i također obuhvaćaju farmaceutski prihvatljive kiselinske ili bazične adicijske soli, stereokemijski izomerne oblike, N-oksidni oblik i predlijekove spoja s tom formulom, pri čemu su svi supstituenti definirani kao u Zahtjevu 1. S obzirom na njihovu sposobnost antagoniziranja djelovanja tahikinina blokiranjem receptora za neurokinin, a naročito antagoniziranjem djelovanja supstance P i Neurokinina B blokiranjem NK, NKi NKreceptora, spojevi u skladu s ovim izumom korisni su kao lijek, posebno u profilaktičkom i terapeutskom liječenju stanja posredovanih tahikininom, kao što su, primjerice, poremećaji CNS-a, posebno shizoaktivni poremećaji, depresija, anksiozni poremećaji, poremećaji povezanih sa stresom, poremećaji spavanja, kognitivni poremećaji, poremećaji ličnosti, poremećaji prehrane, neurodegenerativne bolesti, poremećaji izazvanih ovisnošću, poremećaji raspoloženja, spolna disfunkcija, bol i ostala stanja povezana s CNS-om; upala; alergijski poremećaji; povraćanje; gastrointestinalniporemećaji, posebno sindrom iritabilnog crijeva (IBS); kožni poremećaji; vazospastične bolesti; fibrozne i kolagenske bolesti; poremećaji povezani s pojačanim radom imunološkog sustava ili imunosupresijom i reumatske bolesti te kontrola tjelesne mase.
HRP20050556AA 2002-12-23 2005-06-15 Supstituirani derivati 1-piperidin-4-il-4-pirolidin-3-il-piperazina i njihova upotreba kao antagonista receptora za neurokinin HRP20050556B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0214831 2002-12-23
PCT/EP2003/051041 WO2004056799A2 (en) 2002-12-23 2003-12-17 Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists

Publications (2)

Publication Number Publication Date
HRP20050556A2 HRP20050556A2 (en) 2006-07-31
HRP20050556B1 true HRP20050556B1 (hr) 2014-03-28

Family

ID=32668698

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20050556AA HRP20050556B1 (hr) 2002-12-23 2005-06-15 Supstituirani derivati 1-piperidin-4-il-4-pirolidin-3-il-piperazina i njihova upotreba kao antagonista receptora za neurokinin

Country Status (31)

Country Link
US (1) US7795261B2 (hr)
EP (1) EP1581518B1 (hr)
JP (1) JP4746878B2 (hr)
KR (1) KR101049073B1 (hr)
CN (1) CN100586945C (hr)
AR (1) AR042651A1 (hr)
AT (1) ATE500242T1 (hr)
AU (1) AU2003302488B2 (hr)
BR (1) BR0317658A (hr)
CA (1) CA2508657C (hr)
CL (1) CL2003002725A1 (hr)
CY (1) CY1112601T1 (hr)
DE (1) DE60336266D1 (hr)
DK (1) DK1581518T3 (hr)
EA (1) EA009078B1 (hr)
ES (1) ES2361161T3 (hr)
HK (1) HK1087703A1 (hr)
HR (1) HRP20050556B1 (hr)
IL (1) IL169336A (hr)
JO (1) JO2696B1 (hr)
MX (1) MXPA05006887A (hr)
MY (1) MY145135A (hr)
NO (1) NO331174B1 (hr)
NZ (1) NZ541035A (hr)
PA (1) PA8593301A1 (hr)
PL (1) PL376048A1 (hr)
PT (1) PT1581518E (hr)
SI (1) SI1581518T1 (hr)
TW (1) TWI329109B (hr)
UA (1) UA80584C2 (hr)
WO (1) WO2004056799A2 (hr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847160A1 (fr) * 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
WO2005101838A2 (en) 2004-04-13 2005-10-27 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
WO2005123081A2 (en) * 2004-06-22 2005-12-29 Janssen Pharmaceutica N.V. (2-benzyl-4-{4-[1-(tetrahydrofuran-3-carbonyl)-pyrrolidin-3-yl]-piperazin-1-yl}-piperidin-1-yl)-(3,5-trifluoromethyl-phenyl))-methanone for the treatment of schizophrenia
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7635698B2 (en) * 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
EA014239B1 (ru) * 2005-03-08 2010-10-29 Янссен Фармацевтика Н.В. Производные диаза-спиро-[4,4]нонана в качестве антагонистов нейрокинина (nk1)
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
CA2669917A1 (en) * 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
RU2442786C2 (ru) * 2007-03-31 2012-02-20 Интервет Интернэшнл Б.В. Способы получения зилпатерола и его солей
MX2009010499A (es) 2007-03-31 2009-10-19 Intervet Int Bv Procesos para elaborar zilpaterol y sales del mismo.
KR20140051421A (ko) * 2007-03-31 2014-04-30 인터벳 인터내셔널 비.브이. 질파테롤 및 이의 염의 제조 방법
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2351378T3 (es) * 2007-06-07 2011-02-03 F. Hoffmann-La Roche Ag Derivados de prolinamida como antagonistas de nk3.
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8507535B2 (en) * 2010-07-07 2013-08-13 Hoffmann-La Roche Inc. Methyl-pyrrolidine ether derivatives
KR20150046259A (ko) * 2012-08-23 2015-04-29 앨리오스 바이오파마 인크. 파라믹소바이러스 바이러스성 감염의 치료용 화합물
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2016184829A1 (en) 2015-05-18 2016-11-24 Nerre Therapeutics Limited Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EP3765024B1 (en) 2018-03-14 2023-11-22 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists.
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032867A1 (en) * 2000-10-17 2002-04-25 Glaxo Group Limited Chemical compounds
WO2002062784A1 (en) * 2001-02-06 2002-08-15 F. Hoffmann-La Roche Ag Piperidinee derivatives as neurokinin 1 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW382017B (en) 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
AU7788500A (en) 1999-10-25 2001-05-08 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
FR2820426B1 (fr) * 2001-02-07 2007-05-11 Condat Sa Gel d'isolation thermique a reticulation controlee pour les lignes de transport d'hydrocarbures petroliers
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032867A1 (en) * 2000-10-17 2002-04-25 Glaxo Group Limited Chemical compounds
WO2002062784A1 (en) * 2001-02-06 2002-08-15 F. Hoffmann-La Roche Ag Piperidinee derivatives as neurokinin 1 antagonists

Also Published As

Publication number Publication date
NO20053569D0 (no) 2005-07-21
MXPA05006887A (es) 2005-08-16
TWI329109B (en) 2010-08-21
WO2004056799A3 (en) 2004-08-12
EA200501041A1 (ru) 2005-12-29
AU2003302488B2 (en) 2009-10-08
IL169336A (en) 2013-01-31
AU2003302488A1 (en) 2004-07-14
ATE500242T1 (de) 2011-03-15
EP1581518A2 (en) 2005-10-05
AR042651A1 (es) 2005-06-29
WO2004056799A2 (en) 2004-07-08
NO20053569L (no) 2005-09-15
TW200500359A (en) 2005-01-01
NZ541035A (en) 2008-05-30
ES2361161T3 (es) 2011-06-14
JP4746878B2 (ja) 2011-08-10
UA80584C2 (uk) 2007-10-10
US20060040950A1 (en) 2006-02-23
KR101049073B1 (ko) 2011-07-15
CA2508657C (en) 2013-02-19
EP1581518B1 (en) 2011-03-02
MY145135A (en) 2011-12-30
CL2003002725A1 (es) 2005-04-08
HRP20050556A2 (en) 2006-07-31
US7795261B2 (en) 2010-09-14
CA2508657A1 (en) 2004-07-08
CY1112601T1 (el) 2016-02-10
NO331174B1 (no) 2011-10-24
DK1581518T3 (da) 2011-06-06
BR0317658A (pt) 2005-12-06
CN100586945C (zh) 2010-02-03
CN1726207A (zh) 2006-01-25
PT1581518E (pt) 2011-05-12
IL169336A0 (en) 2007-07-04
JP2006514027A (ja) 2006-04-27
SI1581518T1 (sl) 2011-06-30
KR20050085098A (ko) 2005-08-29
DE60336266D1 (de) 2011-04-14
JO2696B1 (en) 2013-03-03
PL376048A1 (en) 2005-12-12
EA009078B1 (ru) 2007-10-26
HK1087703A1 (en) 2006-10-20
PA8593301A1 (es) 2004-08-31

Similar Documents

Publication Publication Date Title
HRP20050556B1 (hr) Supstituirani derivati 1-piperidin-4-il-4-pirolidin-3-il-piperazina i njihova upotreba kao antagonista receptora za neurokinin
HRP20050309A2 (en) Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists
IL177291A0 (en) Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
CY1109069T1 (el) Ενωσεις ιμιδαζοπυριδαζινης
UA27776C2 (uk) Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
MY134457A (en) Substituted amides
MA29432B1 (fr) Antagonistes du recepteur du glucagon, leur preparation et leurs utilisations therapeutiques
MA29088B1 (fr) Composes d'indazole-carboxamide.
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
DE60312042D1 (de) Substituierte 1-piperidin-4-yl-4-azetidin-3-yl-piperazinderivate und deren verwendung als neurokininantagonisten
WO2006052962A3 (en) Bicyclic triazole a4 integrin inhibitors
ATE449074T1 (de) 2-azabicyclo 3.3.1 nonan-derivate als antagonisten des opioid-rezeptors
EA200701345A1 (ru) Производные триазолона, тетразолона и имидазолона для применения в качестве антагонистов альфа-2с-адренорецептора
HRP20050554B1 (hr) Supstituirani 1- piperidin-3-il-4-piperidin-4-il-piperazinski derivati i njihova primjena kao neurokininskih antagonista
DE69922528D1 (de) N-imidazolyl-alkyl substituierte cyklische amine als histamin-h3 agonisten oder antagonisten
BR0307156A (pt) Derivado de pirimidina bicìclica fundida, composto, antagonistas de receptores e agentes profiláticos e terapêuticos
ATE307814T1 (de) Neue pyridin- und cyclohexenyl-enthaltende pyrrolobenzodiazepin-carboxamide und derivative davon; tokolytische oxytocin-rezeptor- antagonisten
EA200970426A1 (ru) Селективный агонист tr-бета 1
DE602006013040D1 (de) Substituierte pyradinon-derivate als alpha2-adrenorezeptor-antagonisten
JO2526B1 (en) Substituted 1-4 Dipyridine-4-YL-Piprazine derivatives and their use as NSAIDs
MXPA05003778A (es) Derivados sustituidos de la 1,4-di-piperidin-4-il-piperazina y su uso como antagonistas de neurocininas.
UY27135A1 (es) Derivados de imidazolilo como inhibidores del factor de liberación de la corticotropina.
CY1107890T1 (el) Υποκατεστημενα παραγωγα 1-πιπεριδιν-3-υλ-4-πιπεριδιν-4-υλ-πιπεραζινης και χρηση τους ως ανταγωνιστων της νευροκινινης

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20141111

Year of fee payment: 12

PBON Lapse due to non-payment of renewal fee

Effective date: 20151217